TG Therapeutics, Inc. (BIT:1TGTX)

Italy · Delayed Price · Currency is EUR

26.80

-0.71 (-2.58%)

At close: Dec 5, 2025

Market Cap	3.87B
Revenue (ttm)	453.34M
Net Income (ttm)	381.38M
Shares Out	n/a
EPS (ttm)	2.37
PE Ratio	10.14
Forward PE	21.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	27.51
Day's Range	n/a
52-Week Range	22.42 - 40.00
Beta	n/a
RSI	44.03
Earnings Date	Feb 27, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco... [Read more]

Industry Pharmaceutical Preparations

Founded 1993

Employees 338

Stock Exchange Borsa Italiana

Ticker Symbol 1TGTX

Full Company Profile

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD Financial Statements

News

There is no news available yet.